6 completed. 5 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 5 |
| Phase 2 | 3 | Completed 3 |
Follow LY2603618: new trials by email Literature Review of LY2603618 trials Research Report on LY2603618
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine LY2603618, Desipramine, Pemetrexed - Cancer | Phase 1 | Completed | Eli Lilly and Company | 20 | 2011-06-01 | 2018-10-25 |
| A Study of LY2603618 in Combination With Gemcitabine in Participants With Solid Tumors LY2603618, Gemcitabine - Solid Tumors | Phase 1 | Completed | Eli Lilly and Company | 17 | 2011-05-01 | 2019-03-01 |
| A Study in Non Small Cell Lung Cancer Pemetrexed, Cisplatin, LY2603618 - Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Eli Lilly and Company | 76 | 2011-02-01 | 2018-05-18 |
| C14 Study in Oncology Patients With Advanced and/or Metastatic Solid Tumors LY2603618, Pemetrexed, Gemcitabine - Advanced Cancer | Phase 1 | Completed | Eli Lilly and Company | 3 | 2011-02-01 | 2019-01-07 |
| A Study of Advanced or Metastatic Non-small Cell Lung Cancer LY2603618, Pemetrexed - Non Small Cell Lung Cancer | Phase 2 | Completed | Eli Lilly and Company | 55 | 2009-11-01 | 2019-09-17 |
| A Study for Participants With Pancreatic Cancer LY2603618, Gemcitabine - Pancreatic Neoplasms | Phase 1 / Phase 2 | Completed | Eli Lilly and Company | 157 | 2009-02-01 | 2018-04-17 |
Carcinoma, Non-Small-Cell Lung (2) · Carcinoma (1) · Mesothelioma (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Pancreatic Neoplasms (1)
United States (3) · Germany (2) · Italy (2) · Spain (2) · Japan (1) · Netherlands (1) · Romania (1) · South Korea (1) · Switzerland (1) · Taiwan (1)